Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.
Department of Laboratory Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea.
Medicine (Baltimore). 2022 Dec 16;101(50):e32152. doi: 10.1097/MD.0000000000032152.
Patients undergoing maintenance dialysis have a higher mortality rate associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and response rates to vaccination against SARS-CoV-2 vary from 29.6% to 96.4% in such patients. This study aimed to assess the immunogenicity of SARS-CoV-2 vaccination in Korean patients undergoing dialysis. We enrolled 70 SARS-CoV-2-vaccinated patients undergoing dialysis, with 11 healthcare workers serving as healthy control subjects. Thirty-two patients had received a third vaccination, whereas 38 had received 2 vaccinations. The healthy control subjects completed the second vaccination. Immunoglobulin G (IgG) antibodies targeting the receptor-binding domain of the S1 subunit of the SARS-CoV-2 spike protein were measured The vaccination responder rates were 86% (37/43), 96% (26/27), and 91% (10/11) in the patients undergoing hemodialysis and peritoneal dialysis and healthy controls, respectively. IgG antibody levels were significantly higher when a third dose was administered, independent of the type of vaccine or the time interval between vaccination and the subsequent blood sampling date. When a third dose of vaccine was administered, there was no difference in IgG antibody levels between those receiving cross-vaccination or a single vaccine. There was no significant difference in IgG antibodies between healthy controls and patients undergoing dialysis. Patients on dialysis exhibited a sufficient antibody-related response to vaccination against SARS-CoV-2, even in those receiving cross-vaccination, and the antibody titer was higher after a third vaccination. Therefore, it is necessary to administer a third vaccine dose to Korean patients undergoing dialysis.
接受维持性透析的患者因严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染导致的死亡率更高，而此类患者对 SARS-CoV-2 疫苗的反应率在 29.6%至 96.4%之间不等。本研究旨在评估 SARS-CoV-2 疫苗在韩国透析患者中的免疫原性。我们招募了 70 名接受 SARS-CoV-2 疫苗接种的透析患者，其中 11 名医护人员作为健康对照。32 名患者接受了第三次接种，38 名患者接受了两次接种。健康对照完成了第二次接种。测量了针对 SARS-CoV-2 刺突蛋白 S1 亚单位受体结合域的 IgG 抗体。在接受血液透析和腹膜透析以及健康对照组的患者中，疫苗应答率分别为 86%（37/43）、96%（26/27）和 91%（10/11）。当给予第三剂疫苗时，无论疫苗类型如何，以及疫苗接种和随后采血日期之间的时间间隔如何，IgG 抗体水平均显著升高。当给予第三剂疫苗时，接受交叉疫苗接种或单一疫苗接种的患者之间 IgG 抗体水平没有差异。健康对照组和透析患者之间的 IgG 抗体没有差异。接受透析的患者对 SARS-CoV-2 疫苗接种表现出足够的抗体相关反应，即使接受交叉疫苗接种也是如此，并且第三次接种后抗体滴度更高。因此，有必要为韩国透析患者接种第三剂疫苗。
